INTRODUCTION: The risk for development of a second primary lung cancer (SPLC) after treatment of an initial primary lung cancer (IPLC) is around 1% to 2% per patient per year. The present screening and surveillance guidelines do not adequately address this particular patient population. METHODS: We retrospectively reviewed patients in the Surveillance, Epidemiology, and End Results database from 1992 to 2007 to assess the frequency of occurrence of SPLC with regard to multiple patient demographics and calculated standardized incidence ratios (SIRs). RESULTS: The SIRs for SPLCs were high for both men and women at any age but highest if the IPLC occurred at a younger age. Women had the highest SIR values irrespective of age and race, with the highest SIR reported for the youngest age group (20-49 years) (SIR = 15.26, 95% confidence interval: 12.81-18.04). The rate of SPLC development was 1.10% per patient per year, with median time intervals between the IPLC and SPLC diagnoses of 59 and 62 months, respectively, for men and women. The cumulative risk for development of SPLC increased over time and did not plateau. CONCLUSIONS: These findings suggest that there is a continued risk for development of SPLC. Surveillance strategies for this population must be addressed.
INTRODUCTION: The risk for development of a second primary lung cancer (SPLC) after treatment of an initial primary lung cancer (IPLC) is around 1% to 2% per patient per year. The present screening and surveillance guidelines do not adequately address this particular patient population. METHODS: We retrospectively reviewed patients in the Surveillance, Epidemiology, and End Results database from 1992 to 2007 to assess the frequency of occurrence of SPLC with regard to multiple patient demographics and calculated standardized incidence ratios (SIRs). RESULTS: The SIRs for SPLCs were high for both men and women at any age but highest if the IPLC occurred at a younger age. Women had the highest SIR values irrespective of age and race, with the highest SIR reported for the youngest age group (20-49 years) (SIR = 15.26, 95% confidence interval: 12.81-18.04). The rate of SPLC development was 1.10% per patient per year, with median time intervals between the IPLC and SPLC diagnoses of 59 and 62 months, respectively, for men and women. The cumulative risk for development of SPLC increased over time and did not plateau. CONCLUSIONS: These findings suggest that there is a continued risk for development of SPLC. Surveillance strategies for this population must be addressed.
Authors: L Simonato; A Agudo; W Ahrens; E Benhamou; S Benhamou; P Boffetta; P Brennan; S C Darby; F Forastiere; C Fortes; V Gaborieau; M Gerken; C A Gonzales; K H Jöckel; M Kreuzer; F Merletti; F Nyberg; G Pershagen; H Pohlabeln; F Rösch; E Whitley; H E Wichmann; P Zambon Journal: Int J Cancer Date: 2001-03-15 Impact factor: 7.396
Authors: Beate Pesch; Benjamin Kendzia; Per Gustavsson; Karl-Heinz Jöckel; Georg Johnen; Hermann Pohlabeln; Ann Olsson; Wolfgang Ahrens; Isabelle Mercedes Gross; Irene Brüske; Heinz-Erich Wichmann; Franco Merletti; Lorenzo Richiardi; Lorenzo Simonato; Cristina Fortes; Jack Siemiatycki; Marie-Elise Parent; Dario Consonni; Maria Teresa Landi; Neil Caporaso; David Zaridze; Adrian Cassidy; Neonila Szeszenia-Dabrowska; Peter Rudnai; Jolanta Lissowska; Isabelle Stücker; Eleonora Fabianova; Rodica Stanescu Dumitru; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Charles M Rudin; Paul Brennan; Paolo Boffetta; Kurt Straif; Thomas Brüning Journal: Int J Cancer Date: 2011-12-14 Impact factor: 7.396
Authors: Rowan T Chlebowski; Garnet L Anderson; JoAnn E Manson; Ann G Schwartz; Heather Wakelee; Margery Gass; Rebecca J Rodabough; Karen C Johnson; Jean Wactawski-Wende; Jane Morley Kotchen; Judith K Ockene; Mary Jo O'Sullivan; F Allan Hubbell; Jason W Chien; Chu Chen; Marcia L Stefanick Journal: J Natl Cancer Inst Date: 2010-08-13 Impact factor: 13.506
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Matthew B Schabath; Xifeng Wu; Rena Vassilopoulou-Sellin; Ara A Vaporciyan; Margaret R Spitz Journal: Clin Cancer Res Date: 2004-01-01 Impact factor: 12.531
Authors: David Rice; Hyung-Woo Kim; Anita Sabichi; Scott Lippman; J Jack Lee; Brendell Williams; Ara Vaporciyan; W Roy Smythe; Stephen Swisher; Garrett Walsh; Joe B Putnam; Waun Ki Hong; Jack Roth Journal: Ann Thorac Surg Date: 2003-10 Impact factor: 4.330
Authors: Jessica Clague; Peggy Reynolds; Katherine D Henderson; Jane Sullivan-Halley; Huiyan Ma; James V Lacey; Shine Chang; George L Delclos; Xianglin L Du; Michele R Forman; Leslie Bernstein Journal: PLoS One Date: 2014-07-31 Impact factor: 3.240
Authors: Jacqueline V Aredo; Sophia J Luo; Rebecca M Gardner; Nilotpal Sanyal; Eunji Choi; Thomas P Hickey; Thomas L Riley; Wen-Yi Huang; Allison W Kurian; Ann N Leung; Lynne R Wilkens; Hilary A Robbins; Elio Riboli; Rudolf Kaaks; Anne Tjønneland; Roel C H Vermeulen; Salvatore Panico; Loïc Le Marchand; Christopher I Amos; Rayjean J Hung; Neal D Freedman; Mattias Johansson; Iona Cheng; Heather A Wakelee; Summer S Han Journal: J Thorac Oncol Date: 2021-03-17 Impact factor: 20.121
Authors: May Elbanna; Kevin Shiue; Donna Edwards; Alberto Cerra-Franco; Namita Agrawal; Jason Hinton; Todd Mereniuk; Christina Huang; Joshua L Ryan; Jessica Smith; Vasantha D Aaron; Heather Burney; Yong Zang; Jordan Holmes; Mark Langer; Richard Zellars; Tim Lautenschlaeger Journal: Clin Lung Cancer Date: 2020-06-02 Impact factor: 4.785